Immune-mediated inflammatory diseases (IMIDs) are characterized by excessive and
uncontrolled inflammation and thrombosis, both of which are responsible for organ damage …

Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

Objective While endothelial dysfunction has been implicated in the widespread
thromboinflammatory complications of COVID‐19, the upstream mediators of …

Autoimmune diseases are associated with a dramatically increased risk of atherosclerotic
cardiovascular disease and its clinical manifestations. The increased risk is consistent with …

Despite major advances in acute interventions for myocardial infarction (MI), adverse
cardiac remodeling and excess fibrosis after MI causing ischemic heart failure (IHF) remain …

BACKGROUND: Anti-β2GP1 (β2-glycoprotein 1) antibodies are the primary pathogenic
antibody to promote thrombosis in antiphospholipid syndrome (APS), yet the underlying …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease, where persistent
presence of antiphospholipid antibodies (aPL) leads to thrombotic and obstetric …

Lysosomes catabolize and recycle lipids and other biological molecules to maintain cellular
homeostasis in diverse nutrient environments. Lysosomal lipid catabolism relies on the …

Tissue factor pathway inhibitor (TFPI) is an alternatively spliced anticoagulant protein that
primarily dampens the initiation phase of coagulation before thrombin is generated. As such …

Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a
recently described autoinflammatory syndrome characterized by diffuse inflammatory …